Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations
Tóm tắt
Từ khóa
Tài liệu tham khảo
Riihimaki, 2014, Metastatic sites and survival in lung cancer, Lung Cancer, 86, 78, 10.1016/j.lungcan.2014.07.020
Yano, 1994, Local recurrence after complete resection for non–small-cell carcinoma of the lung. Significance of local control by radiation treatment, J Thorac Cardiovasc Surg, 107, 8, 10.1016/S0022-5223(94)70445-7
Heitmann, 2018, Perspectives on oligometastasis: challenges and opportunities, J Thorac Dis, 10, 113, 10.21037/jtd.2017.12.77
Forde, 2013, Targeted therapy for non–small-cell lung cancer: past, present and future, Expert Rev Anticancer Ther, 13, 745, 10.1586/era.13.47
Herbst, 2011, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non–small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial, Lancet, 377, 1846, 10.1016/S0140-6736(11)60545-X
Seto, 2014, Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non–small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, Lancet Oncol, 15, 1236, 10.1016/S1470-2045(14)70381-X
Wu, 2013, Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non–small-cell lung cancer (FASTACT-2): a randomised, double-blind trial, Lancet Oncol, 14, 777, 10.1016/S1470-2045(13)70254-7
Goldberg, 2013, Chemotherapy with erlotinib or chemotherapy alone in advanced non–small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors, Oncologist, 18, 1214, 10.1634/theoncologist.2013-0168
Salama, 2008, An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease, Clin Cancer Res, 14, 5255, 10.1158/1078-0432.CCR-08-0358
Inoue, 2010, Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions, Jpn J Clin Oncol, 40, 788, 10.1093/jjco/hyq044
Pfannschmidt, 2010, Surgical treatment of oligometastatic non–small cell lung cancer, Lung Cancer, 69, 251, 10.1016/j.lungcan.2010.05.003
Khan, 2006, Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non–small cell lung carcinoma (NSCLC), Radiat Oncol, 81, 163, 10.1016/j.radonc.2006.09.006
Yano, 2010, Prognostic impact of local treatment against postoperative oligometastases in non–small cell lung cancer, J Surg Oncol, 102, 852, 10.1002/jso.21750
Weichselbaum, 2011, Oligometastases revisited, Nat Rev Clin Oncol, 8, 378, 10.1038/nrclinonc.2011.44
Goldstraw, 2016, The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer, J Thorac Oncol, 11, 39, 10.1016/j.jtho.2015.09.009
Palma, 2014, The oligometastatic state—separating truth from wishful thinking, Nat Rev Clin Oncol, 11, 549, 10.1038/nrclinonc.2014.96
Patel, 2012, A call for the aggressive treatment of oligometastatic and oligo-recurrent non–small cell lung cancer, Pulm Med, 2012, 480961, 10.1155/2012/480961
Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study, Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0
Wong, 2016, Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT), Cancer, 122, 2242, 10.1002/cncr.30058
De Leyn, 2008, Survival after resection of synchronous bilateral lung cancer, Eur J Cardiothorac Surg, 34, 1215, 10.1016/j.ejcts.2008.07.069
He, 2017, Surgical treatment in non–small cell lung cancer with pulmonary oligometastasis, World J Surg Oncol, 15, 36, 10.1186/s12957-017-1105-8
Ashworth, 2014, An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer, Clin Lung Cancer, 15, 346, 10.1016/j.cllc.2014.04.003
Jiang, 2016, EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases, J Thorac Oncol, 11, 1718, 10.1016/j.jtho.2016.05.013
Lin, 2016, Enhancing anticancer effect of gefitinib across the blood–brain barrier model using liposomes modified with one alpha-helical cell–penetrating peptide or glutathione and Tween 80, Int J Mol Sci, 17, 10.3390/ijms17121998
Yang, 2017, Icotinib versus whole-brain irradiation in patients with EGFR-mutant non–small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial, Lancet Respir Med, 5, 707, 10.1016/S2213-2600(17)30262-X
Baykara, 2014, Management of brain metastases from non–small cell lung cancer, J Cancer Res Ther, 10, 915, 10.4103/0973-1482.137939
D’Antonio, 2014, Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies, Ther Adv Med Oncol, 6, 101, 10.1177/1758834014521110
Collen, 2014, Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients, Ann Oncol, 25, 1954, 10.1093/annonc/mdu370